Tomorrow's Vision. Today's Reality.

In today's New Health, market authorization for a new therapeutic is only the first stage in a biopharmaceutical product's lifecycle. A product must also satisfy further scrutiny by key stakeholders, each with specific ideas regarding what success really means:

  • Physicians desire further evidence of a new product's effectiveness
  • Patients demand more assurance regarding a drug's safety
  • Payers want demonstrable proof of a therapy's value
  • Policy-makers look for confirmation of a real-world risk/benefit profile in large populations

Late Phase (Phase IIIB/ Phase IV and real-world observational research) is absolutely critical to addressing the needs of these stakeholders and consequently increasing predicted demand for these services in the coming years.